---
title: About Us
description: >-
  OM1 pioneers AI-powered real-world data to measure outcomes, accelerate
  research & improve clinical decisions. 10+ patents since 2017. Boston-based.
date: '2026-11-12'
category: Page
canonical_url: https://www.om1.com/about-us/
source: om1
license: © 2026 OM1. All rights reserved.
slug: about-us
id: 3WxWXXxVXN7MhrwCalunXK
contentType: page
---

# About Us

At OM1, outcomes come first—because they’re what matter most in healthcare.

![Hero Collage About](https://images.ctfassets.net/ddhe5ahaolzf/1fAyb80aCJkblNw4L9EHex/003b8cb8c67b1cb118eb5419eed346b7/hero-collage-about.jpg?w=1064&fm=webp&q=75)


- [Get in Touch](https://www.om1.com/contact-us/#form) 

## Our Mission

We unlock the power of healthcare data to measure and predict outcomes, accelerate medical research, and improve clinical decision-making.

## Leadership

### [Richard Gliklich, MD](https://www.om1.com/team/richard-gliklich/)

![Rich Gliklich Sq](https://images.ctfassets.net/ddhe5ahaolzf/4OnPbSn42aUqFjeLsrWyDu/26d5bf8499fe4532c753fccac19f165a/rich-gliklich-sq.png?w=600&fm=webp&q=75)

Dr. Richard Gliklich, MD is the founder of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles.



Dr. Gliklich is well known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices.



Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.



### [Catherine Richards, PhD, MPH](https://www.om1.com/team/catherine-richards/)

![Catherine Richards Sq](https://images.ctfassets.net/ddhe5ahaolzf/3pBgY6QlFL2Lc20DqbykGc/23b42f3fa6c047a24256aa5350e5d092/catherine-richards-sq.png?w=1096&fm=webp&q=75)

Catherine Richards is the President & COO at OM1, inc. In her role as president Catherine is responsible for leading OM1’s four business units: Data & Insights, Clinical Registries & Automated Studies, Research Services and PhenOM®, as well as leads technology and compliance, all with the goal of ensuring a thriving company culture that delivers significant value to customers.

Prior to OM1 Catherine was the Chief Data Officer & General Manager of the Real World Evidence business unit at ConcertAI, where she was responsible for a 600+ person global team that created and delivered data products, custom data solutions and outcomes science services to the pharmaceutical industry.

Before ConcertAI, she was the Senior Vice President of Analytics & Scientific Engagement at Panalgo, where she led data integration, data operations and scientific engagement, including training and supporting users of Instant Health Data (IHD).

Previous to Panalgo she was the Director of User and Scientific Engagement for Aetion, supporting the use and adoption of the Aetion Evidence Platform and working as the scientific lead for five of the top 20 pharmaceutical companies.

Proceeding Aetion she was a staff scientist at the Hutchinson Institute for Cancer Outcomes Research (HICOR) at Fred Hutch in Seattle, Washington. While there the main focus of her research and academic activities was on improving the quality of cancer care while reducing the economic burden for patients and society.

Catherine received her MPH and PhD in Cancer Epidemiology from the Mailman School of Public Health At Columbia University.



### [Dan Levy, MS](https://www.om1.com/team/dan-levy/)

![Dan Levy Sq](https://images.ctfassets.net/ddhe5ahaolzf/faUUealBs9QJwGQj6tG8R/833bc5ef07b26abefcc692030003234a/dan-levy-sq.png?w=1116&fm=webp&q=75)

Dan Levy is the Chief Data Officer at OM1, Inc. In his role, Dan is responsible for developing and managing the partner ecosystem, with a focus on creating data solutions that generate value to both OM1 customers and partners.

For the prior 4 years, Dan was Chief Technology Officer at Amazing Charts, an ambulatory electronic medical record and health IT company. Dan led the software engineering, quality assurance, cloud operations, and data & analytics functions, and helped lead the company through an acquisition to Harris Healthcare. For the 8 years prior, Dan served as Vice President of Engineering and later as Chief Technology Officer at Outcome Sciences, a division of Quintiles, focusing on real-world and late phase research. Prior to that, Dan held a number of technical leadership roles in both public and private, venture backed companies.

Dan received a BA in General Science from Brandeis University and an MS in Software Engineering from Boston University.



### [Rich Jenkins](https://www.om1.com/team/rich-jenkins/)

![Rich Jenkins Sq](https://images.ctfassets.net/ddhe5ahaolzf/2f3n5BBW8Sav16YqTD6dJr/b6bf476fca8a3cd59ab9988443fb8693/rich-jenkins-sq.png?w=702&fm=webp&q=75)

Rich Jenkins is the Chief Commercial Officer at OM1. He has 25 years experience in the life sciences technology and real-world research space. Rich spent the previous 6 years as Chief Growth Officer at Aetion, where he led their significant growth in the RWE market. Formerly the global head of Real-World and Late Phase Business Development with IQVIA, Rich was responsible for developing and leading go-to-market strategy for IQVIA’s Real-World Insights business. Richard joined IQVIA (Quintiles) through the acquisition of Outcome Sciences. Prior to joining Outcome Sciences, Rich helped launch and spent seven years with IntraLinks, an online secure platform supporting information for clinical trials, M&A due diligence, and syndicated financing. He played a critical role in transitioning the core customer base from financial services and legal to key stakeholders across the life sciences industry.

Jenkins holds a Bachelor's of Engineering in Electrical Engineering from Stony Brook University.



### [Carl Marci, MD](https://www.om1.com/team/carl-marci/)

![Carl Marci Sq](https://images.ctfassets.net/ddhe5ahaolzf/3xUShEiMdyPPx2fYIZs5R8/7b68c90d0884fb37116357f32c2183f3/carl-marci-sq.png?w=538&fm=webp&q=75)

Dr. Carl Marci is the Chief Clinical Officer and Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. Previously, he was Chief Psychiatrist and Chief Medical Officer at several venture backed health and technology companies, and is a 2023** **[**PharmaVoice 100 Honoree**](https://www.pharmavoice.com/news/pharmavoice100-pv100-pharma-leaders/690951/#dr-carl-marci).

Dr. Marci is board certified and is part-time staff at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School, he completed two NIH Fellowships in neuroscience and has published numerous articles in peer-review science journals. He holds seven patents and is the author of a book on the impact of technology on the brain.

Dr. Marci is a graduate of Columbia University and Oxford University where he was a Rhodes Scholar. He then went to Harvard Medical School and graduated with honors; he is also the former Director of Social Neuroscience at Massachusetts General Hospital.



### [Costas Boussios, PhD](https://www.om1.com/team/costas-boussios/)

![Costas Boussios Sq](https://images.ctfassets.net/ddhe5ahaolzf/6AppjwFiSH2tQEjz8xWgPA/2438b889d310ac8a7083cc8045b0a6c0/costas-boussios-sq_1.png?w=1200&fm=webp&q=75)

Costas Boussios, PhD, is the Chief Data Scientist at OM1, where he leads Research and Development for the PhenOM® AI Platform, built to advance medical research and personalize medicine. Dr. Boussios is a co-inventor on 9 issued US patents in healthcare AI, focusing on areas such as patient phenotyping and subtyping, AI explainability, and the impact of relative timing on outcomes. He has co-authored peer-reviewed research on AI and machine learning applications in rare conditions, multiple sclerosis, rheumatoid arthritis, lupus, depression, and metabolic liver disease. Before joining OM1, Dr. Boussios served as Chief Data Scientist at Mitra Capital LLC, recognized as the world’s top-performing equity market neutral hedge fund by net return rates in 2015. His background also includes leading Data Science teams in credit scoring. Dr. Boussios earned his PhD in Mechanical Engineering from MIT, specializing in machine learning and feedback control systems.



### [Eric Schrock](https://www.om1.com/team/eric-schrock/)

![Eric Schroc Sq](https://images.ctfassets.net/ddhe5ahaolzf/M4X6F4K9M5tFDBc0WcpWE/94f6e788a6f83e021a2638bbe016744b/eric-schroc-sq.png?w=468&fm=webp&q=75)

Eric Schrock is the Chief Technology Officer at OM1, Inc. In this role, he is responsible for the Product Engineering, Data Engineering, IT, and Security teams that develop and operate OM1's technology platform and products.

Prior to OM1, Eric was the Chief Technology Officer and Co-CEO at Jvion, a clinical AI company that uses prescriptive intelligence to improve patient outcomes. There, he ran the engineering, data science, professional services, and customer success teams responsible for product development and delivery. Prior to Jvion, Eric was VP of Engineering and CTO at Delphix, a data virtualization company that simplifies the delivery of secure production data to enterprise teams. Early in his career, Eric developed complex enterprise software systems including operating systems, filesystems, and hardware storage appliances.



### [Hunter Lane](https://www.om1.com/team/hunter-lane/)

![Hunter Lane Sq](https://images.ctfassets.net/ddhe5ahaolzf/5a2udhnqRvlMjMavpw1GF2/0315fcdafd091b8ab89261680ad01a42/hunter-lane-sq.png?w=600&fm=webp&q=75)

Hunter Lane is the Chief Product Officer at OM1, where he leads Product and Engineering to deliver AI-enabled real-world evidence platforms that accelerate research, commercialization, and healthcare improvement.

With over 15 years of experience in healthcare technology, Hunter most recently served as Senior Director of Product at Tempus, where he launched its flagship platform and helped grow its genomics business to $452M in annual revenue. His work supported over half of U.S. oncologists and fueled research at 95% of the top 20 pharma companies. He also led the development of Tempus One, a generative AI assistant for healthcare professionals.

Hunter has built and scaled products that bring next-generation sequencing, clinical trial matching, and AI-powered tools into clinical workflows. He has led high-performing teams across four continents and played a key role in multiple successful startup exits. He holds several patents in health data and AI, lectures on healthcare innovation at Northwestern’s MBAi program, and holds a degree in International Business from Loyola University Chicago.



### [Dennis Reilly](https://www.om1.com/team/dennis-reilly/)

![Dennis Reilly Sq](https://images.ctfassets.net/ddhe5ahaolzf/79hQAUj8tMpNCKDD3aiWiM/394575b6aad358550139ddfcd87dbf4f/dennis-reilly-sq.png?w=600&fm=webp&q=75)

Dennis Reilly is the Chief Financial Officer at OM1, Inc. Prior to joining OM1, he was the VP, Finance at Aptus Health, a global digital health company acquired by WebMD. Prior to Aptus, Dennis worked at several venture-backed healthcare technology companies.

Dennis began his career at Arthur Andersen as a CPA and corporate auditor. He received his BS from Merrimack College.



### [Ashish Deshpande](https://www.om1.com/team/ashish-deshpande/)

![Ashish Deshpande Isolated sq](https://images.ctfassets.net/ddhe5ahaolzf/1hyoeHeCpicwSFFm0a7ECZ/cddad4eb01245a561bc69bb524d4e820/Ashish_Deshpande_Isolated_sq.png?w=1200&fm=webp&q=75)

Dr. Ashish Deshpande, MD, MS,** **is a Physician, Vice President & Head of Clinical Informatics at OM1.  Ashish is OM1’s subject matter expert on effective data management, development, maintenance, and the implementation of informatics tools and processes for standardized & normalized high-quality data for outcomes research & analytics. Before OM1, Dr. Deshpande was a Clinical Advisory Architect with IBM Watson Health within their Solutions & Services portfolio, strategizing clinical as well as financial analytics strategies for larger Healthcare Systems and Clinically Integrated Networks. Dr. Deshpande has also worked in the Clinical Informatics field at Explorys, leading Content Development & Client Implementation teams, creating newer Analytic Content targeted towards Population Health, Value-Based Care, and Clinical Outcomes. Dr. Deshpande is trained in Internal Medicine and worked as a Hospitalist prior to moving into Clinical Informatics, and also holds a Masters degree in Applied Anatomy with targeted research in the fields of Multiple Sclerosis and Developmental Neurology from Case Western Reserve University.



### [Tiffany Hadzi](https://www.om1.com/team/tiffany-hadzi/)

![Tiffany Hadzi](https://images.ctfassets.net/ddhe5ahaolzf/4auGZjxqz3prqZW8XpYNAM/3e534df91289fea8a0f0e53400e5c0b4/Tiffany_Hadzi.png?w=1200&fm=webp&q=75)

Tiffany Hadzi, MPH**, **is a VP of Client Services at OM1, where she works with clients to ensure programs are managed efficiently and with high levels of communication. Prior to OM1, Tiffany was at GNS Healthcare, where she founded the project management department overseeing three business units. Before GNS, she was at Boston University School of Medicine, where she managed NIH funded research studies.



### [Eric Mertz](https://www.om1.com/team/eric-mertz/)

![Eric Mertz isolated sq](https://images.ctfassets.net/ddhe5ahaolzf/1tbusIyONXUHw4ecXjYSWw/9501d2b8ab0fa512dfa3ef5fda8a5b48/Eric_Mertz_isolated_sq.png?w=1200&fm=webp&q=75)

Eric Mertz is Vice President and General Manager, Europe at OM1. He serves as Executive Sponsor and primary Business Relationship Lead for Novo and brings deep experience in building and scaling high-performing operational teams, while forging strategic partnerships across Europe. Eric has an extensive track record delivering real-world evidence (RWE) solutions for pharmaceutical companies, payers, and regulators, and has been a key contributor to risk-sharing agreements and real-world data strategy across multiple therapeutic areas. He has built and led cross-functional teams across Europe and Japan, successfully scaling operations to support the delivery of complex RWE programs in global markets. A proven leader in digital health, he has also integrated advanced analytics into real-world research, helping life science partners unlock value from complex data assets and accelerate evidence generation. Eric holds an MBA from ESCM Business School in Montpellier, France, and a Bachelor’s Degree from the University Robert Schuman in Strasbourg, France.






### [Ombretta Palucci](https://www.om1.com/team/ombretta-palucci/)

![Ombretta Palucci isolated sq](https://images.ctfassets.net/ddhe5ahaolzf/4vqBkXQ5DGGHA4DOk23dVX/5da2bb09529ddbb58ff2ec0371cd0038/Ombretta_Palucci_isolated_sq.png?w=1200&fm=webp&q=75)

Ombretta Palucci is Vice President and Head of Operations, Europe at OM1. Based in Switzerland, she is a pharmaceutical scientist with more than 20 years of leadership in real-world evidence, registries, post-marketing studies, and observational research across Europe. Ombretta brings deep expertise in designing and operationalizing complex registries and has significant experience in global and multi-country studies. Previously, at IQVIA and PAREXEL, she led solution design and delivery for large-scale real-world programs, including oversight of observational studies, pragmatic trials, safety surveillance, and registries. She has extensive experience in global study operations covering regulatory submissions, CRO and vendor management, site activation, patient enrollment, and ethics approvals. She has also managed international teams of up to 100 staff, leading budgets, client engagements, proposal defenses, and business development initiatives. Ombretta holds a Master’s Degree in Pharmaceutical Chemistry and Technology (110/110 cum laude) from the Università degli Studi, Siena, Italy.






## Our History

OM1 pioneered the use of AI in real-world data long before it became mainstream. Since launching our first dataset and AI model in 2017, we’ve helped healthcare organizations harness deep, longitudinal data and predictive intelligence to close evidence gaps and improve outcomes. Built on a decade of innovation, we continue to redefine what’s possible in healthcare.

The name OM1 reflects our purpose: “O” for Outcomes, “M” for Measurement, and “1” for our belief that better outcomes are the first step toward better healthcare.

![Om1 Logomark Starburst Rev](https://images.ctfassets.net/ddhe5ahaolzf/1shXjnKXSY4n4kT7vcgK4Z/9c9a9e021948f68058765148068c6930/om1-logomark-starburst-rev.svg)

## 10 AI Technology Patents and Counting

###### OM1 has been awarded 10 patents in leading AI technology, including digital phenotyping 
and subtyping, explainability and outcomes measurement.

- **2025** — Health care information system providing additional data fields in patient data
- **2025 **— Applying predictive models to data representing a history of events
- **2025** — Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions
- **2024 **— Health care information system providing standardized outcome scores across patients
- **2024** — Health care information system providing additional data fields in patient data
- **2024** — Applying predictive models to data representing a history of events
- **2024** — Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions
- **2023** — Health care information system providing additional data fields in patient data
- **2023** — Health care information system providing standardized outcome scores across patients
- **2022** — Information system providing explanation of models



![Innovation Bg Datafield Sq](https://images.ctfassets.net/ddhe5ahaolzf/6egFIc3SHiJ4dbS0mKbRso/5bb5d49ee0ea795bd5db40f3c41d851d/innovation-bg-datafield.jpg?w=1200&fm=webp&q=75)

## EcoVadis Sustainability Rating

EcoVadis is a globally recognized assessment that evaluates a company's corporate social responsibility (CSR) and environmental, social, and governance (ESG) management systems. 

OM1 earned a Gold Medal, a recognition awarded to the Top 5% of companies assessed by EcoVadis. It reflects the quality of the OM1's sustainability management system and demonstrates a commitment to promoting transparency throughout the value chain.



![EcoVadis Gold Badge](https://images.ctfassets.net/ddhe5ahaolzf/6raJZIy9kKc0nzih3kh4lP/88bd9e8e08eea3bf96a960b83e842826/medal.png?w=1667&fm=webp&q=75)


- [Learn More About Our EcoVadis Rating](https://recognition.ecovadis.com/nAgjvjF7MU6uIF4iNWuziA) 

## Want to help us reimagine healthcare with AI and clinical data?

At OM1, our team combines data science, clinical expertise, engineering, and innovation to solve some of the most complex challenges in healthcare. If you’re driven by purpose, passionate about technology that makes a measurable impact, and excited to shape the future of healthcare, we’d love to meet you.

Explore open roles or reach out at [careers@om1.com](mailto:careers@om1.com)




![Collab Office Cowork Meeting (circle)](https://images.ctfassets.net/ddhe5ahaolzf/3JMYP6Bj1efyiMZ4O9lERH/7e8a9ccf1d7c03fe24f02acef4cf6b81/collab-office-cowork-meeting-2400.jpg?w=2400&fm=webp&q=75)


- [View Job Openings](https://job-boards.greenhouse.io/om1) 

## Latest News & Articles

- [OM1 Rheumatoid Arthritis Dataset Rated High Quality as Cornerstone AI Partnership Speeds Future Quality Reviews](https://www.businesswire.com/news/home/20250821833445/en/OM1-Rheumatoid-Arthritis-Dataset-Rated-High-Quality-as-Cornerstone-AI-Partnership-Speeds-Future-Quality-Reviews)
- [OM1 expands neurology network to over 3 million patients for real-world data research](https://becarispublishing.com/digital-content/blog-post/om1-expands-neurology-network-over-3-million-patients-real-world-data-research)
- [OM1 Adds a Half Million Patients to Neurology Network, Strengthening Real-World Evidence Generation and Accelerating Innovation in Neurology](https://www.businesswire.com/news/home/20250812898616/en/OM1-Adds-a-Half-Million-Patients-to-Neurology-Network-Strengthening-Real-World-Evidence-Generation-and-Accelerating-Innovation-in-Neurology)

### Get In Touch

31 St. James Ave Suite #1010
Boston MA, 02116
[+1 (888) 324 3899](tel:+18883243899)
[info@om1.com](mailto:info@om1.com)



*Patients should contact their health provider directly with questions about their health or completing an assessment.

### Ready to accelerate evidence generation?


- [Book a Demo](https://www.om1.com/request-a-demo/) 

*Interactive embed: Fin.*

